Want to see TSE:ADK full AI Analyst Report?
Top Page
Diagnos
(ADK)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.41
▲(0.00% Upside)
Action:Reiterated
Date:10/14/26
The score is primarily weighed down by poor financial performance—shrinking revenue, large ongoing losses, and sustained negative operating/free cash flow with a relatively fragile balance sheet. Technicals are also weak with oversold momentum and the price below the 20-day average, offering only limited support. Valuation is not clearly compelling because the negative P/E is driven by unprofitability and there is no dividend yield.
Positive Factors
Diagnostic Imaging Focus
Diagnos operates in medical imaging and decision-support, giving it a business focus tied to disease detection and assessment. If its technologies gain adoption, software-enabled diagnostic solutions could support scalable commercialization and create a durable niche in healthcare information services.
Negative Factors
Revenue Contraction
The sharp multi-year revenue decline shows that Diagnos has not maintained commercial scale across the reported period. Shrinking sales reduce operating leverage, constrain investment in product development and commercialization, and make a near-term path to sustainable earnings more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Diagnostic Imaging Focus
Diagnos operates in medical imaging and decision-support, giving it a business focus tied to disease detection and assessment. If its technologies gain adoption, software-enabled diagnostic solutions could support scalable commercialization and create a durable niche in healthcare information services.
Read all positive factors
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$55.99M
Dividend YieldN/A
Average Volume (3M)215.69K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-36.92%
EPS Growth13.03%
CountryCA
Employees16
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume187,879
30 Day Avg. Volume215,695
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Diagnos Business Overview & Revenue Model
Company Description
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations ...
How the Company Makes Money
null...
Diagnos Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.48K | 103.80K | 170.16K | 267.07K | 331.52K |
| Gross Profit | -119.45K | -943.56K | 35.80K | -347.53K | -473.45K |
| EBITDA | -4.13M | -3.56M | -2.45M | -2.45M | -1.91M |
| Net Income | -4.56M | -4.29M | -3.12M | -2.05M | -3.38M |
Balance Sheet | |||||
| Total Assets | 2.39M | 3.64M | 663.79K | 1.95M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 3.24M | 219.01K | 1.36M | 1.87M |
| Total Debt | 1.40M | 3.07M | 3.19M | 471.68K | 337.55K |
| Total Liabilities | 1.70M | 3.40M | 3.72M | 818.19K | 614.78K |
| Stockholders Equity | 686.90K | 233.11K | -3.05M | 1.13M | 1.82M |
Cash Flow | |||||
| Free Cash Flow | -4.01M | -3.65M | -2.16M | -1.40M | -2.66M |
| Operating Cash Flow | -4.00M | -3.64M | -2.15M | -1.36M | -2.64M |
| Investing Cash Flow | 1.56M | -3.11M | -14.02K | 262.93K | -759.98K |
| Financing Cash Flow | 2.66M | 6.62M | 2.08M | 882.82K | 3.83M |
Diagnos Technical Analysis
Neutral
0.41
Price Trends
0.44
Negative
0.33
Positive
0.31
Positive
Market Momentum
<0.01
Positive
36.62
Neutral
18.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Neutral. The current price of 0.41 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.44, and above the 200-day MA of 0.31, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 36.62 is Neutral, neither overbought nor oversold. The STOCH value of 18.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ADK.
Diagnos Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | C$57.72M | -2.04 | -444.52% | ― | 415.06% | -54.80% | |
43 Neutral | C$55.99M | -10.29 | 9999.00% | ― | -36.92% | 13.03% | |
43 Neutral | C$8.20M | -2.52 | 355.56% | ― | 614.03% | 51.97% | |
42 Neutral | C$2.25M | -0.77 | 184.91% | ― | ― | 43.30% | |
42 Neutral | C$5.26M | -2.58 | 739.84% | ― | ― | -28.35% | |
41 Neutral | C$9.86M | -1.67 | 64.52% | ― | 7.63% | -106.03% |
* General Sector Average
TSE:ADK
Diagnos
0.43
0.04
11.84%
TSE:AIDR
Rocket Doctor AI
0.55
-0.15
-21.43%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.34
-0.06
-15.00%
TSE:UDOC
UniDoc Health Corp
0.10
-0.14
-58.70%
TSE:NARA
PanGenomic Health, Inc. Class A
0.16
-1.84
-92.00%
TSE:DMED
DiagnaMed Holdings Corp.
0.04
-0.06
-60.00%
Diagnos Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Diagnos Seeks U.S. FDA Clarity on AI-Powered CARA Eye Screening System
Positive
Sep 28, 2026
Diagnos has submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration regarding the classification and regulatory requirements of its CARA System, following an earlier FDA pre-submission and responding to a specif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.